Details

Autor(en) / Beteiligte

• García‐Doval, I.
• Hernández, M.V.
• Vanaclocha, F.
• Sellas, A.
• Cueva, P.
• Montero, D.
• Rodríguez, Basilio
• Barceló, Mireia
• Farietta, Sandra
• Montoro, María
• González, Ainhoa
• Herráez, Elena
• Ruíz‐Montesino, Mª Dolores
• Vargas, Carmen
• Pérez‐Pampín, Eva
• Ortiz, Ana Mª
• Tomero, Eva
• Sifuentes, Alberto
• Antón, Fred
• Zea, Antonio
• Manero Ruiz, Francisco Javier
• Beltrán, Chesús
• Giménez Úbeda, Eugenio
• Jimenez Zorzo, Fernando
• Marzo, Jesús
• Medrano, Marta
• Pecondón, Ángela
• Sanmartí, Raimon
• Cañete, Juan D.
• Rodriguez Lozano, Carlos
• Naranjo, Antonio
• Ojeda, Soledad
• Hernández, Félix Francisco
• Erausquin, Celia
• Rúa, Íñigo
• Quevedo, Juan Carlos
• Manrique, Sara
• Ureña, Inmaculada
• Irigoyen, María Victoria
• Cano, Laura
• Pardo, Rosa Roselló
• Mateo, Isabel
• Garcia, Javier
• Enríquez, Eugenia
• Campos, Cristina
• García Borras, Juan José
• Nogueroles, Rosa
• Muñoz, Luisa
• Luis Valero, José
• Ibáñez, Andrés
• Carretero Hernández, Gregorio
• Torrado, Rosa
• Carrascosa Carrillo, José Manuel
• Ferrándiz, Carlos
• Rivera, Raquel
• Dauden, Esteban
• Llamas, Mar
• Mejías, Sagrario Galiano
• Gómez García, Francisco José
• Jiménez Puya, Rafael
• Herrera, Enrique
• Mendiola, Mª Victoria
• Belinchón Romero, Isabel
• Sánchez Carazo, José Luis
• López Estebaranz, José Luis
• Ruiz Genao, Diana
• Alsina, Mercè
• Ferran, Marta

Titel

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

Ist Teil von

• British journal of dermatology (1951), 2017-03, Vol.176 (3), p.643-649

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Summary Background Information on the safety of tumour necrosis factor (TNF) antagonists frequently arises from their use in rheumatic diseases, their first approved indications, and is later applied to psoriasis. Whether the risk of biological therapy is similar in psoriasis and rheumatoid arthritis has been considered a priority research question. Objectives To compare the safety profile of anti‐TNF drugs in patients with rheumatoid arthritis and psoriasis. Methods We compared two prospective safety cohorts of patients with rheumatoid arthritis and psoriasis that share methods (BIOBADASER and BIOBADADERM). Results There were 1248 serious or mortal adverse events in 16 230 person‐years of follow‐up in the rheumatoid arthritis cohort (3171 patients), and 124 in the 2760 person‐years of follow‐up of the psoriasis cohort (946 patients). Serious and mortal adverse events were less common in patients with psoriasis than in rheumatoid arthritis (incidence rate ratio of serious adverse events in psoriasis/rheumatoid arthritis: 0·6, 95% confidence interval 0·5–0·7). This risk remained after adjustment for sex, age, treatment, disease, hypertension, diabetes, hypercholesterolaemia and simultaneous therapy with methotrexate (hazard ratio 0·54, 95% confidence interval 0·47–0·61), and after excluding patients receiving corticosteroids. Patients with rheumatoid arthritis showed a higher rate of infections, cardiac disorders, respiratory disorders and infusion‐related reactions, whereas patients with psoriasis had more skin and subcutaneous tissue disorders and hepatobiliary disorders. Conclusions Patients with rheumatoid arthritis clinical practice have almost double the risk of serious adverse events compared with patients with psoriasis, with a different pattern of adverse events. Safety data from rheumatoid arthritis should not be fully extrapolated to psoriasis. These differences are likely to apply to other immune‐mediated inflammatory diseases. What's already known about this topic? Safety results from the use of biologics in some immune‐mediated inflammatory diseases, such as rheumatoid arthritis, are frequently applied to others, such as psoriasis. What does this study add? Safety results from studies of rheumatoid arthritis patients are not fully applicable to psoriasis patients, as the rate of serious adverse events in rheumatoid arthritis patients is almost double, and the pattern of adverse events is different. Linked Comment: Puig. Br J Dermatol 2017; 176:567–568.